Assay May Prevent Unnecessary Repeat Prostate Biopsies – Renal and Urology News
Epigenetic assay has a high negative predictive value for prostate cancer.
Epigenetic assay has a high negative predictive value for prostate cancer.
ASCO GU 2025 cabazitaxel vs lutetium Lu-177 vipivotide tetraxetan, metastatic castration-resistant prostate cancer (mCRPC),
ASCO GU 2025 PORTOS, PORTOS as a predictor of radiation dose response in prostate cancer, showing benefits in phase III trials and its link to…
ASCO GU 2025 metastatic castration-sensitive prostate cancer (mCSPC), homologous recombination repair (HRR) genes, ADP-ribose polymerase (PARP) inhibitors, Metastatic Prostate Cancer Clinico-Genomic Database (CGDB).
ASCO GU 2025, Advanced Prostate Cancer, LuCarbo Trial, 177Lu-PSMA-617, Carboplatin, LuPSMA.
Eric Kim discusses the variation in prostate cancer genomic subtypes related to MRI PI-RADS scores and racial differences. He focused on the correlations between mpMRI…
NUBEQA® (darolutamide), ARANOTE, ARASENS, ARAMON, ARASTEP, XOFIGO® (radium-223 dichloride), metastatic castration-resistant prostate cancer, biochemically recurrent prostate cancer.
cancer disparities, Mobile Prostate Cancer Screening Clinic, American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, prostate-specific antigen (PSA) screening, PI-RADS score.
ASCO GU, Prostate Cancer, pylarify, piflufolastat F 18, piflufolastat F 18 data.
Zachary Klaassen interviews Oliver Sartor about three significant prostate cancer trials presented at ESMO 2024. Dr. Sartor discusses the ARANOTE, PEACE-3, and the SPLASH trials.…
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer. This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Matthew…